VivoSim Labs, Inc. · Moat analysis

Report previewVIVS.USReport date Last updated
← Back to reports
Report contents
01

Industry landscape

Where the company competes: simulation is a label, not a market boundary

Market definition: unresolved. VivoSim Labs (VIVS.US) cannot yet be placed in a named sub-industry, and that gap is the first thing to close, not a formality. A company called a simulation business could be selling software licenses to drug-discovery teams, hardware-and-software training rigs to hospitals, or contract modeling services to manufacturers. Those are three different arenas with different buyers, different contract lengths and different incumbents. Until one of them is named, any statement about VivoSim's competitive position is a statement about the word "simulation," not about the company.

The distinction is not academic, because the arena sets who holds bargaining power along the chain. Take the two ends of the plausible range. A vendor selling validated modeling software into regulated life-sciences workflows sits downstream of a small number of large buyers who qualify vendors slowly and switch rarely; the vendor's pricing power depends on switching costs embedded in validation paperwork, and on whether the underlying compute or assay inputs come from suppliers with their own leverage. A vendor selling simulation training equipment sits downstream of hospital or plant procurement committees that tender on price and service coverage, upstream of hardware suppliers, and its margin depends on installation and service density by geography. In the first, the software link tends to capture the margin; in the second, the service network does. Which one VivoSim occupies determines whether scale is a national or a local variable, and that in turn decides whether the moat question is about installed base or about route density.

Three disclosures would fix the boundary

Segment revenue shares are the starting point. A single reported segment that mixes license, service and hardware revenue tells an investor nothing about where the profit is earned, because the three carry different gross margins and different repeat characteristics. A breakout by product line, even two lines, would show which link in the chain VivoSim actually monetizes.

Geographic revenue shares come second, and they carry the scale question. If revenue concentrates in one country, the competitive arena is national and the relevant rivals are domestic; if it spreads across regions with separate regulatory regimes, the company is running several local businesses under one ticker, and share gains in one region say nothing about another. The geographic split also exposes currency and tender-cycle exposure that a consolidated growth rate hides.

Customer concentration comes third. A customer accounting for a tenth or more of revenue changes the bargaining picture outright: renewal pricing then depends on one counterparty's alternatives, and the moat test moves from "does the product win in a competitive field" to "can the company hold price at the next renewal." A dispersed customer base supports the opposite reading.

What a competitor count would settle

The practical test for entry barriers is whether the meaningful players in the named submarket fit on one hand. That requires a dated, sourced share table for the specific arena, not for simulation at large. Nothing in the record reviewed here supplies one, and the absence is decisive rather than incidental: without a named field, there is no way to tell a concentrated niche with certification-driven entry costs from a fragmented field where a dozen vendors compete on features and price. Those two structures imply opposite conclusions about durability, and both remain open.

What would move this forward is narrow and checkable. One dated estimate of the relevant submarket's size and the top three to five vendors' shares, from an industry tracker or a trade association, would let the concentration and barrier tests run. Failing that, two consecutive years of VivoSim's own segment revenue alongside a named rival's disclosure would show relative direction, though not level. Until one of those exists, the honest position is that the company competes somewhere real, and the work of saying where has not been done.

02

Competitive advantage

Does the company have a moat? No, because there is no revenue base to protect

Moat rating: None. VivoSim Labs reported no meaningful revenue in any fiscal year from FY2022 through FY2026, and its return on assets was negative in all five. The clearest figures are -23.7% in FY2025 and -125.6% in FY2026, the latter meaning the loss exceeded the entire asset base. A moat protects above-normal returns from being competed away. VivoSim has no above-normal returns, so the barrier question has nothing to attach to yet.

The point a reader might miss is that the gross margin looks like a franchise and is not one. It sits at 100% in four of the five years from FY2022 to FY2026, the profile of a royalty or license business with no cost of goods. At VivoSim's scale that line measures the absence of a delivered product: revenue is small enough that a percentage margin carries no information. In the quarter ended September 30, 2026 the gross margin swings to -6,502% on negative gross profit, which is what these ratios look like when the denominator is a rounding error.

Biotechnology moats sit on a marketed product or a validated platform: patent exclusivity that holds price, or proprietary data and process that lower the cost of discovery. Concentration matters in that industry because development is a large fixed cost that only a real revenue base carries. VivoSim sits upstream of the question. Its revenue is not small against a market total; it is small against its own operating costs.

Market position: unmeasurable, and the base shrank about 90%

Market position: None. No share figure with a year and a named source places VivoSim in any defined submarket, and its revenue is too small to register against a published market total. Ranking is not established.

Stability: None. Fewer than three reliable years of share data exist, so stability cannot be confirmed. Revenue direction is readable. Asset turnover multiplied by total assets, both reported by the company, implies revenue of roughly $1.0–1.4 million in FY2022 and roughly $60,000–$140,000 in FY2026, a decline of about 90% (estimated; both inputs are rounded). Companies that hold their customers do not post that path.

Returns: negative ROA every year, with no long-term debt to blame

Profitability: None. ROE ran -33.0% in FY2022, -75.8% in FY2023, -155.0% in FY2024, -35.3% in FY2025 and -294.8% in FY2026. ROE is the wrong headline here: after accumulated losses, equity is near zero or negative in several periods, so the ratio mostly reflects a shrinking denominator. ROA is cleaner and negative throughout, at -31.3%, -64.4%, -110.1%, -23.7% and -125.6%.

An after-tax ROIC would not tell us much. Operating income is negative and invested capital has been eaten down by deficits, so the ratio would describe the denominator, not the business; ROE and ROA serve as substitutes. The balance sheet carries no long-term debt, so leverage is not producing these negative returns. The operations are.

The rule of thumb for a durable advantage is average after-tax ROIC of 15%–25% over a decade or more, with 6%–8% usually indicating none. VivoSim is not at the low end of that band. It is below zero, and the open question is whether a positive return will ever appear.

Scale and margins: the asset base is roughly eighty times revenue

Scale and margins: None. Asset turnover of 0.012 in FY2026 means the company holds about eighty dollars of assets for every dollar of annual revenue. Net margin was -10,567% in FY2026 and -1,728% in FY2025. Both numbers are arithmetically correct and analytically bare: they show a cost base that is an organization, not a production function. Scale here works against the company, since fixed costs are spread over a base that is shrinking rather than growing.

Overall: none, with profitability carrying the decision

Overall rating: None. Profitability decides it, and profitability is negative on every measure across five fiscal years. Market position cannot be measured, and revenue ran the wrong way. The sub-ratings agree, so there is no gap to explain. VivoSim does not have a narrowing moat. It has yet to build the revenue base a moat would have to protect.

Where the advantage comes from and how long it can last: the only candidate asset earns nothing

With no returns in place, the question becomes which structural source could exist and what the record says about it. For a biotechnology company the candidates are narrow: patent or regulatory exclusivity on a compound or platform, which is supply side; switching costs inside validated research or clinical workflows, which is demand side; and scale in development or manufacturing. Brand, capital and being early are execution, and execution gets copied. These three sources matter for this sub-industry because each would leave a financial trace that can be checked.

Supply side: a working patent estate would show up as royalties

Supply-side advantage: None established. The only supply-side asset that could matter at this size is intellectual property: a patent estate, a regulatory exclusivity position, or proprietary data that shortens discovery. If one were working, its signature would be a licensing or royalty stream with high incremental margin and stable or growing revenue, and the 100% gross margin would carry real information because it would describe a protected product delivered at almost no marginal cost.

VivoSim reports that margin without the stream. Gross profit has been essentially equal to revenue in every year, which at this scale means a few hundred thousand dollars at most, and the revenue path runs the wrong way for a royalty business. A patent estate generating royalties does not shrink toward zero; a license that ran off, or a product that never reached scale, does. Patents are also the most time-limited of the three sources: they publish, they expire, and their value is realized only through a partner, a trial or a sale. The adverse outcome to follow is another year of revenue under $150,000 while operating costs stay in the millions. If that repeats, the intellectual property is not converting into a return, and the claim fails on its own evidence.

Demand side: switching costs are real in this industry, the renewals are not

Demand-side advantage: None established. Switching costs are the most plausible protection VivoSim could have. Research and clinical workflows are validated, documented and slow to change, so software and reference data embedded in them can be genuinely sticky: requalification costs time and creates business risk, and a rival's discount does not easily dislodge an incumbent. That mechanism is real in this industry, which is why the demand side deserves the closest look.

Captivity has a financial fingerprint, though. Renewal pricing holds, revenue per customer is stable or rising, and accounts do not leave quietly. VivoSim shows the reverse: a decline of roughly 90% over four years is what losing accounts looks like, and it is hard to reconcile with customers who are locked in and paying. Time is the second constraint. Cash was about $10 million at September 30, 2026, against FY2026 operating cash outflow reported at roughly $5–15 million, which funds about a year at that pace before outside capital is needed. Validation-driven captivity takes years to build. A company with roughly twelve months of runway cannot wait out that clock, and a financing raised at a low price would dilute the claim on whatever the installed base is worth.

Scale: the fixed cost is development and the base cannot carry it

Scale advantage: None. Fixed costs in biotechnology are development programs, regulatory work and specialized staff, and minimum efficient scale (the volume at which one product can carry its own development cost) is set by getting a product to approval. VivoSim's 0.012 asset turnover says that base is spread over almost no volume, and the base is shrinking: total assets fell from roughly $30 million in FY2022 to roughly $10 million at September 30, 2026 as losses consumed the balance sheet. Scale as a barrier also needs customers who stay; without them, a larger fixed base is a cost disadvantage. What would break this reading is a partnership that shifts development cost to a counterparty while leaving VivoSim the economics, which is the one route by which a company this size buys scale with someone else's balance sheet.

What to measure: revenue per dollar of operating expense

The single test that most directly settles the moat is how much revenue the organization generates for each dollar it spends. In FY2026 that ratio was roughly half a cent to three cents (estimated from rounded figures): revenue in the low six figures against an operating loss in the $5–15 million range. A biotechnology company with a durable advantage moves that ratio toward and past one, because a protected product eventually carries the cost of the people and facilities around it. A ratio stuck below 0.05 while costs hold says the organization is funding activity, not a franchise.

Two questions follow. Does any single product or license account for most of the revenue, and is that revenue renewing at a stable price? And can VivoSim fund the several years a validation-driven or patent-driven advantage needs, without a financing that resets the equity story? Two or three annual reports will answer the first. The cash balance answers the second sooner.

Generated by DeepVal AI. Data and models may contain errors or be outdated. For research only; not personalized investment advice.

Continue the comparison

Continue reading the full report

  1. Comparison and summaryHow VivoSim Labs, Inc. compares with its closest rivals, and our moat rating

Free to sign up · 20 research points · unlocking this report uses 10

20 points cover 2 full reports. No card needed.

Research reflects its generation date. Preview the first two modules.

More on VivoSim Labs, Inc.